Skip to main content
PARADIGM BIOPHARMACEUTICALS LIMITED.. logo

PARADIGM BIOPHARMACEUTICALS LIMITED.. — Investor Relations & Filings

Ticker · PAR ISIN · AU000000PAR5 LEI · 984500AED3956615CA10 ASX Professional, scientific and technical activities
Open in API
Filings indexed 689 across all filing types
Latest filing 2026-05-11 Proxy Solicitation & In…
Country AU Australia
Listing ASX PAR

About PARADIGM BIOPHARMACEUTICALS LIMITED..

https://paradigmbiopharma.com/

Paradigm Biopharmaceuticals Limited is a late-stage drug development company focused on repurposing Pentosan Polysulfate Sodium (PPS) for the treatment of inflammatory diseases and regenerative medicine. The company's primary clinical program targets Osteoarthritis (OA), where its lead candidate, Zilosul, aims to address pain and structural progression by inhibiting inflammatory pathways and promoting tissue repair. Additionally, Paradigm is exploring the efficacy of PPS in treating rare diseases such as Mucopolysaccharidosis (MPS). By leveraging the established safety profile of an existing pharmaceutical agent, the company seeks to accelerate the delivery of transformative therapies to patients with significant unmet medical needs in the musculoskeletal and lysosomal storage disorder markets. Its approach combines proprietary intellectual property with clinical data to validate PPS as a potential disease-modifying treatment.

Recent filings

Filing Released Lang Actions
Notice of General Meeting/Proxy Form 27 pages 606.1KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a combined Notice of General Meeting and Explanatory Statement, setting out resolutions to be voted on by shareholders, along with proxy voting instructions. It is clearly a proxy solicitation/information statement for a shareholder meeting and not the financial report itself or an announcement of publication. Therefore, it falls under Proxy Solicitation & Information Statement (PSI).
2026-05-11 English
Becoming a substantial holder 17 pages 1.9MB
Major Shareholding Notification Classification · 95% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001, detailing substantial shareholding information for Allianz SE and related entities in Paradigm Biopharmaceuticals Ltd. It includes voting power, relevant interests, registered holders, consideration paid, and associates. The document also contains detailed appendices listing entities and ownership percentages, and references to consolidated financial statements notes. The primary content is a regulatory disclosure of a major shareholding position, not a financial report, earnings release, or management discussion. This fits the definition of a Major Shareholding Notification (MRQ). The document length is substantial and contains detailed shareholding data, confirming it is not a brief announcement or a certification. Therefore, the correct classification is MRQ with high confidence.
2026-05-04 English
Application for quotation of securities - PAR 6 pages 18.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue price, and issued capital following quotation. It references a previous Appendix 3B announcement related to the securities issuance. The document is a formal announcement related to capital market activities, specifically the quotation of new securities following a prior issuance announcement. This fits the category of Share Issue/Capital Change (SHA), as it concerns the issuance and quotation of new shares. The document is not a full financial report, earnings release, or management discussion, but a regulatory announcement about capital changes.
2026-04-30 English
Cleansing Notice 1 page 193.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 1 May 2026 from Paradigm Biopharmaceuticals Limited. It is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the completion of a placement of shares and compliance with disclosure requirements. The text details the issuance of shares by placement and references compliance with specific sections of the Corporations Act. It also mentions a forthcoming share purchase plan. The document is short (1658 characters) and serves as a formal announcement of a capital raising event rather than a full financial report or detailed analysis. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2026-04-30 English
DSMB 20% Review Supports Phase 3, Moldova Activated 2 pages 152.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 30 April 2026 from Paradigm Biopharmaceuticals providing an update on the progress of a Phase 3 clinical trial, including safety review results, site activation, recruitment status, and interim analysis timing. It contains no financial statements or detailed financial data, nor does it present full financial results or management discussion of financial performance. The content is primarily a clinical trial progress update and operational status announcement. It is not a report like an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a regulatory filing or certification. The document is a capital/financing update type of announcement related to clinical trial progress, which is often material to investors and can impact company valuation and financing. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length is about 4811 characters, which is consistent with a detailed announcement but not a full report. Confidence is high given the clear nature of the content and absence of financial data or other report types.
2026-04-29 English
Share Purchase Plan - Offer Booklet 10 pages 319.0KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Paradigm Biopharmaceuticals Limited regarding a Share Purchase Plan (SPP) and a Placement of shares. It includes specifics about the number of shares to be issued, pricing, eligibility, use of funds, timetable, and regulatory compliance references such as ASX Listing Rules and ASIC Corporations Instrument. The content focuses on capital raising activities, share issuance, and related terms and conditions. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but an update on financing and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the capital raising event, supporting a high confidence level.
2026-04-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.